Faricimab was approved in Europe for treating macular oedema due to retinal vein occlusion. The German Institute for Quality and Efficiency in Health Care examined its benefits over other therapies but found no proof of added benefit. Studies comparing faricimab with aflibercept did not meet specified treatment regimens, making the assessment inconclusive. The manufacturer did not follow recommendations to conduct a study with a treat-and-extend dosing regimen. In contrast, a study comparing brolucizumab and aflibercept for macular degeneration used a treat-and-extend regimen effectively. The G-BA will make the final decision on the extent of added benefit.
Source link
Faricimab lacks proof of added benefit over comparator therapies for macular edema
